Atmeksi is a drug owned by Rosemont Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 09, 2044. Details of Atmeksi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12390439 | Oral Liquid Formulation Of Methocarbamol |
Oct, 2044
(18 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Atmeksi's patents.
Latest Legal Activities on Atmeksi's Patents
Given below is the list of recent legal activities going on the following patents of Atmeksi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 26 Aug, 2025 | US12390439 |
| Email Notification | 19 Aug, 2025 | US12390439 |
| Patent Issue Date Used in PTA Calculation | 19 Aug, 2025 | US12390439 |
| Mail Patent eGrant Notification | 19 Aug, 2025 | US12390439 |
| Recordation of Patent eGrant | 19 Aug, 2025 | US12390439 |
| Patent eGrant Notification | 19 Aug, 2025 | US12390439 |
| Email Notification | 07 Aug, 2025 | US12390439 |
| Issue Notification Mailed | 06 Aug, 2025 | US12390439 |
| Application Is Considered Ready for Issue | 25 Jul, 2025 | US12390439 |
| Dispatch to FDC | 25 Jul, 2025 | US12390439 |
US patents provide insights into the exclusivity only within the United States, but
Atmeksi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Atmeksi's family patents as well as insights into
ongoing legal events
on those patents.
Atmeksi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Atmeksi's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 09, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Atmeksi Generic API suppliers:
Methocarbamol is the generic name for the brand Atmeksi. 51 different companies have already filed for the generic of Atmeksi, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Atmeksi's generic
About Atmeksi
Atmeksi is a drug owned by Rosemont Pharmaceuticals Inc. Atmeksi uses Methocarbamol as an active ingredient. Atmeksi was launched by Rosemont in 2025.
Approval Date:
Atmeksi was approved by FDA for market use on 30 July, 2025.
Active Ingredient:
Atmeksi uses Methocarbamol as the active ingredient. Check out other Drugs and Companies using Methocarbamol ingredient
Dosage:
Atmeksi is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 750MG/5ML | SUSPENSION | Prescription | ORAL |